Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer

Author(s): Kevin M. Sokolowski, Steven Koprowski, Selvi Kunnimalaiyaan, Mariappan Balamurugan, T. Clark Gamblin, Muthusamy Kunnimalaiyaan.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry

Volume 16 , Issue 1 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Primary liver cancer is one of the most commonly occurring cancers worldwide. Hepatocellular carcinoma (HCC) represents the majority of primary liver cancer and is the 3rd most common cause of cancer-related deaths globally. Survival rates of patients with HCC are dependent upon early detection as concomitant liver dysfunction and advanced disease limits traditional therapeutic options such as resection or ablation. Unfortunately, at the time of diagnosis, most patients are not eligible for curative surgery and have a five-year relative survival rate less than 20%, leading to systemic therapy as the only option. Currently, sorafenib is the only approved systemic therapy; however, it has a limited survival advantage and low efficacy prompting alternative strategies. The inception of sorafenib for HCC systemic therapy and the understanding involved of cancer therapy have led to an enhanced focus of the PI3-k/Akt/mTOR pathway as a potential area of targeting including pan and isoform-specific PI3-K inhibitors, Akt blockade, and mTOR suppression. The multitude, expanding roles, and varying clinical trials of these inhibitors have led to an increase in knowledge and availability for current and future studies. In this review, we provide a review of the literature with the aim to focus on potential targets for HCC therapies as well as an in depth focus on Akt inhibition.

Keywords: Akt inhibition, hepatocellular carcinoma, MK2206, PI3K/Akt/mTOR, sorafenib.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2016
Page: [29 - 37]
Pages: 9
DOI: 10.2174/1871520615666150716104408

Article Metrics

PDF: 62
HTML: 4
EPUB: 3
PRC: 1